Lantheus Holdings, Inc.

LNTH ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $233.6M $312.4M $326.7M $28.1M $-71.3M $-13.5M $31.7M $40.5M
Depreciation & Amortization $70.1M $64.6M $60.0M $47.9M $42.3M $24.7M $13.4M $13.9M
Depreciation — — — — — — — —
Amortization $47.1M $43.8M $46.4M $33.2M $27.5M $10.8M $1.8M $2.6M
Stock-Based Compensation $85.6M $76.4M $50.5M $29.3M $15.9M $14.1M $12.5M $8.7M
Net Cash from Operating Activities $390.1M $544.8M $305.3M $281.8M $53.9M $16.4M $80.4M $61.2M
Investing Activities
Capital Expenditures — — $45.3M $260.0M $0 $0 $22.1M $20.1M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-627.2M $-226.0M $5.9M $-276.5M $3.7M $-4.9M $-22.1M $-19.1M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases $300.0M $100.0M $0 $75.0M $0 $0 — —
Net Cash from Financing Activities $-316.6M $-118.5M $-13.1M $311.7M $-39.3M $-21.9M $-78.9M $-4.7M
Net Change in Cash $-553.7M $199.2M $298.0M $316.6M $18.0M $-10.2M $-20.5M $37.1M
Free Cash Flow — — $259.9M $21.8M $53.9M $16.4M $58.3M $41.1M
← Newer Page 1 of 2 Older →